Table 3.
Adverse Effects of Cediranib using Common Toxicity Criteria (CTC) Version 4.0
| AE Category | 0 | 1 | 2 | 3 | 4 | 5 | Total |
|---|---|---|---|---|---|---|---|
| Leukopenia | 40 | 7 | 1 | 0 | 0 | 0 | 48 |
| Thrombocytopenia | 38 | 9 | 1 | 0 | 0 | 0 | 48 |
| Neutropenia | 44 | 3 | 1 | 0 | 0 | 0 | 48 |
| Anemia | 37 | 7 | 4 | 0 | 0 | 0 | 48 |
| Other Investigations | 21 | 17 | 8 | 2 | 0 | 0 | 48 |
| Ear and labyrinth | 45 | 2 | 1 | 0 | 0 | 0 | 48 |
| Endocrine | 35 | 5 | 8 | 0 | 0 | 0 | 48 |
| Eye | 46 | 0 | 2 | 0 | 0 | 0 | 48 |
| Nausea | 28 | 10 | 10 | 0 | 0 | 0 | 48 |
| Vomiting | 35 | 6 | 5 | 2 | 0 | 0 | 48 |
| Other Gastrointestinal | 9 | 20 | 10 | 9 | 0 | 0 | 48 |
| General and administration site | 7 | 15 | 16 | 10 | 0 | 0 | 48 |
| Infections/Infestations | 46 | 0 | 2 | 0 | 0 | 0 | 48 |
| Injury/poisoning | 47 | 1 | 0 | 0 | 0 | 0 | 48 |
| Metabolism/nutrition | 24 | 12 | 8 | 4 | 0 | 0 | 48 |
| Musculoskeletal/connective tissue | 40 | 4 | 2 | 2 | 0 | 0 | 48 |
| Peripheral sensory neuropathy | 42 | 5 | 1 | 0 | 0 | 0 | 48 |
| Nervous system | 33 | 11 | 4 | 0 | 0 | 0 | 48 |
| Psychiatric | 47 | 1 | 0 | 0 | 0 | 0 | 48 |
| Renal/urinary | 38 | 4 | 6 | 0 | 0 | 0 | 48 |
| Respiratory/thoracic/mediastinal | 37 | 7 | 3 | 1 | 0 | 0 | 48 |
| Skin/subcutaneous | 41 | 6 | 1 | 0 | 0 | 0 | 48 |
| Vascular disorders | 15 | 2 | 13 | 18 | 0 | 0 | 48 |